Crispr stock price prediction

image

CRISPR Therapeutics stock price prediction is an act of determining the future value of CRISPR Therapeutics shares using few different conventional methods such as EPS estimation, analyst consensus, or fundamental intrinsic valuation. The successful prediction of CRISPR Therapeutics’ future price could yield a significant profit.

Stock Price Forecast

The 23 analysts offering 12-month price forecasts for CRISPR Therapeutics AG have a median target of 112.00, with a high estimate of 220.00 and a low estimate of 46.00. The median estimate represents a +76.85% increase from the last price of 63.33.

Full
Answer

Are CRISPR stocks a good investment?

There are good investments and there are great investments. CRISPR Therapeutics ( NASDAQ:CRSP) stock certainly qualifies as the latter. This is a company that, four years after it went public, has only been profitable for one year, yet its future is so promising that its stock is trading for 540% more than it did in 2016.

How to invest in CRISPR?

The Best CRISPR Companies to Invest In

  • CRISPR companies forging the future. Several companies are using CRISPR to edit human genomes in an attempt to treat (and even cure) genetic diseases.
  • 5 best CRISPR stocks to buy. Not every investor will want to buy CRISPR gene-editing stocks. …
  • Beam Therapeutics. …
  • CRISPR Therapeutics. …
  • Editas Medicine. …
  • Intellia Therapeutics. …
  • Verve Therapeutics. …

What is CRSP stock?

  • Get a free copy of the StockNews.com research report on CRISPR Therapeutics (CRSP)
  • MarketBeat: Week in Review 2/7 – 2/11
  • Can Uber (NYSE: UBER) Get Back On Track?
  • The Institutions Are Buying Newell Brands, Maybe You Should Too
  • Western Digital Stock is Ready to Pick Up
  • 3 Brawny International Stocks to Add to Your Portfolio

How do you use CRISPR?

  • Production of an inhibitor may be made constant and at high concentration.
  • Modifying the operator, or the represser, or or the inducer, to block the progress of RNA polymerase .
  • Alternatively, RNA polymerase binding can be blocked
image


Is CRSP stock a good buy?

Out of 14 analysts, 4 (28.57%) are recommending CRSP as a Strong Buy, 5 (35.71%) are recommending CRSP as a Buy, 5 (35.71%) are recommending CRSP as a Hold, 0 (0%) are recommending CRSP as a Sell, and 0 (0%) are recommending CRSP as a Strong Sell.


What will CRSP stock be worth in 2025?

CRISPR Therapeutics (CRSP -5.41%), a company leaning on gene-editing technology to precisely alter genomic DNA and tackle hard-to-treat diseases, is expected to see sales climb from $719,000 in 2020 to a consensus of $1.377 billion by 2025.


Is Crispr stock a buy or sell?

CRISPR Therapeutics has received a consensus rating of Buy. The company’s average rating score is 2.60, and is based on 9 buy ratings, 6 hold ratings, and no sell ratings.


Will gene stock go up?

Based on our forecasts, a long-term increase is expected, the “GENE” stock price prognosis for 2027-06-23 is 3.094 USD. With a 5-year investment, the revenue is expected to be around +141.69%. Your current $100 investment may be up to $241.69 in 2027.


Is Crispr undervalued?

At a high level, most CRISPR stocks are wildly overvalued given their level of maturity. Unlike software companies, it’s very difficult for a drug developer to reach a market valuation of $10 billion.


Who owns Crispr stock?

Top 10 Owners of CRISPR Therapeutics AGStockholderStakeShares ownedBlackRock Fund Advisors2.53%1,962,052Loomis, Sayles & Co. LP1.67%1,290,905Fidelity Management & Research Co…1.63%1,261,622The Vanguard Group, Inc.1.51%1,170,3366 more rows


What is the best CRISPR stock to buy?

5 best CRISPR stocks to buyCompanyMarket CapCRISPR Therapeutics (NASDAQ:CRSP)$6.1 billionEditas Medicine (NASDAQ:EDIT)$1.9 billionIntellia Therapeutics (NASDAQ:NTLA)$8.9 billionVerve Therapeutics (NASDAQ:VERV)$1.9 billion1 more row•Jan 7, 2022


Why are CRISPR stocks falling?

Rising research and development (R&D) expenses have led to expanding losses for CRISPR Therapeutics, and the relatively nascent state of the company’s treatment catalog and pipeline means that the business is still posting minuscule revenue.


Will CRSP stock go up?

Stock Price Forecast The 23 analysts offering 12-month price forecasts for CRISPR Therapeutics AG have a median target of 112.00, with a high estimate of 220.00 and a low estimate of 46.00. The median estimate represents a +76.85% increase from the last price of 63.33.


What is the best genomic stock to buy?

Illumina. Illumina is the industry leader in using short-read sequencing technology, which breaks DNA into short segments to aid in analysis for genetic research, testing, and medical treatment. … Pacific Biosciences of California. … Exact Sciences. … Invitae. … Fulgent Genetics. … Intellia Therapeutics. … CRISPR Therapeutics.


What is the number 1 DNA stock?

Illumina1. Illumina. Since its founding in 1998, Illumina has become an industry leader with more than 90% of the global sequencing market and an installed base of more than 17,000 sequencing systems. Human DNA contains 3.05 billion base pairs.


How do I buy CRISPR stock?

How to buy shares in Crispr TherapeuticsCompare share trading platforms. Use our comparison table to help you find a platform that fits you.Open your brokerage account. Complete an application with your details.Confirm your payment details. … Research the stock. … Purchase now or later. … Check in on your investment.


Stock Price Forecast

The 20 analysts offering 12-month price forecasts for CRISPR Therapeutics AG have a median target of 145.00, with a high estimate of 220.00 and a low estimate of 64.00. The median estimate represents a +149.66% increase from the last price of 58.08.


Analyst Recommendations

The current consensus among 24 polled investment analysts is to Buy stock in CRISPR Therapeutics AG. This rating has held steady since February, when it was unchanged from a Buy rating. Move your mouse over past
months for detail


Historical and forecast chart of CRISPR Therapeutics stock

The chart below shows the historical price of CRISPR Therapeutics stock and a prediction chart for the next year. For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast, and Weighted Average Best Forecast.


CRISPR Therapeutics information and performance

CRISPR Therapeutics AG engages in the development and commercialization of therapies derived from genome-editing technology. Its proprietary platform CRISPR/Cas9-based therapeutics allows for precise and directed changes to genomic DNA.


CRISPR Therapeutics price target for 2021 by month

The weighted average target price per CRISPR Therapeutics share in Jan 2025 is: 62.87. In Jan, the negative dynamics for Momo shares will prevail with possible monthly volatility of 13.725% volatility is expected.


CRSP : CRISPR Therapeutics AG stock forecast by Wall Street Analysts

The average CRISPR Therapeutics AG stock forecast from last 6 month is $125.0, and this show a -16.72% decrease in average from the prior price target of the each prediction. Also, this average forecast of $125.0 represents a -20.09% decrease from the past average forecast of $156.43, 6 months ago from 7 wall street analysts.


Frequently Asked Questions about CRISPR Therapeutics AG stock forecast

From CRISPR Therapeutics AG stock forecast , CRISPR Therapeutics AG (CRSP) stock can be a good investment choice. According to AI Pickup, the CRISPR Therapeutics AG stock price forecast for 2022 Mar. is $64.6320763969938


Signals & Forecast

There are mixed signals in the stock today. The CRISPR Therapeutics AG stock holds a buy signal from the short-term moving average; at the same time, however, the long-term average holds a general sell signal.


Support, Risk & Stop-loss

CRISPR Therapeutics AG finds support from accumulated volume at $59.00 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.


Is CRISPR Therapeutics AG stock A Buy?

CRISPR Therapeutics AG holds several positive signals, but we still don’t find these to be enough for a buy candidate. At the current level, it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development.


Insiders are neutral selling more shares than they are buying in CRISPR Therapeutics AG

In the last 100 trades there were 1.08 million shares bought and 1.39 million shares sold. The last trade was done 9 days ago by Smith Brendan who bough 15.3 thousand shares. In general the insiders are selling more stocks than they buy. There can be a variety of reasons for this, but in general it can be considered as a negative signal.


Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.
This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!


Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.


CRISPR Therapeutics AG Stock Forecast

Over the next 52 weeks, CRISPR Therapeutics AG has on average historically risen by 55.4 % based on the past 5 years of stock performance.


Will CRISPR Therapeutics AG Stock Go Up Next Year?

Over the next 52 weeks, CRISPR Therapeutics AG has on average historically risen by 55.4% based on the past 5 years of stock performance.


CRISPR Therapeutics AG Stock Price History

Based on the share price being below its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bearish and CRSP is experiencing slight selling pressure.


Stock Predictions

Is CRISPR Therapeutics AG stock public?
Yes, CRISPR Therapeutics AG is a publicly traded company.


Historical and forecast chart of CRISPR Therapeutics stock

The chart below shows the historical price of CRISPR Therapeutics stock and a prediction chart for the next month. For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast, and Weighted Average Best Forecast.


CRISPR Therapeutics Daily Price Targets

Forecast target price for 02-26-2022: $ 52.99. Negative dynamics for CRISPR Therapeutics shares will prevail with possible volatility of 3.149%.


CRISPR Therapeutics forecast for this year

An uptrend is forecast for this month with an optimal target price of $ 65.005. Pessimistic: $59.49. Optimistic: $70.52


CRISPR Therapeutics information and performance

CRISPR Therapeutics AG engages in the development and commercialization of therapies derived from genome-editing technology. Its proprietary platform CRISPR/Cas9-based therapeutics allows for precise and directed changes to genomic DNA.


Analyst price target for CRSP

Based on 9 analyst s offering 12 month price targets for CRISPR Therapeutics AG.


CRSP earnings per share forecast

What is CRSP ‘s earnings per share in the next 3 years based on estimates from 13 analyst s?


CRSP revenue forecast

What is CRSP ‘s revenue in the next 3 years based on estimates from 8 analyst s?


CRSP revenue growth forecast

How is CRSP forecast to perform vs Biotechnology companies and vs the US market?

image

Leave a Comment